These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34029536)

  • 1. Ensuring fair distribution of COVID-19 vaccines: is an intellectual waiver the answer?
    Burki TK
    Lancet Respir Med; 2021 Jul; 9(7):e64. PubMed ID: 34029536
    [No Abstract]   [Full Text] [Related]  

  • 2. Intellectual property waiver for covid-19 vaccines will advance global health equity.
    Erfani P; Binagwaho A; Jalloh MJ; Yunus M; Farmer P; Kerry V
    BMJ; 2021 Aug; 374():n1837. PubMed ID: 34344728
    [No Abstract]   [Full Text] [Related]  

  • 3. What next for a COVID-19 intellectual property waiver?
    Zarocostas J
    Lancet; 2021 May; 397(10288):1871-1872. PubMed ID: 34022975
    [No Abstract]   [Full Text] [Related]  

  • 4. A patent waiver on COVID vaccines is right and fair.
    Nature; 2021 May; 593(7860):478. PubMed ID: 34035532
    [No Abstract]   [Full Text] [Related]  

  • 5. An African plan to control COVID-19 is urgently needed.
    The Lancet
    Lancet; 2020 Dec; 396(10265):1777. PubMed ID: 33278920
    [No Abstract]   [Full Text] [Related]  

  • 6. Don't worry about the drug industry's profits when considering a waiver on covid-19 intellectual property rights.
    Hawksbee L; McKee M; King L
    BMJ; 2022 Jan; 376():e067367. PubMed ID: 35101900
    [No Abstract]   [Full Text] [Related]  

  • 7. [Access to anti-covid vaccines: research, development and role of patents.].
    Formoso G; Mancini S
    Recenti Prog Med; 2021; 112(7):499-503. PubMed ID: 34263876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suspend intellectual property rights for covid-19 vaccines.
    Krishtel P; Malpani R
    BMJ; 2021 May; 373():n1344. PubMed ID: 34049897
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessment of the proposed intellectual property waiver as a mechanism to address the COVID-19 vaccine scarcity problem.
    Barnes-Weise J; Santos Rutschman A; Adler R
    J Epidemiol Community Health; 2022 Apr; 76(4):317-318. PubMed ID: 35140119
    [No Abstract]   [Full Text] [Related]  

  • 10. Innovation alone won't end COVID-19.
    Amin T
    Nat Hum Behav; 2022 Feb; 6(2):172-173. PubMed ID: 35102360
    [No Abstract]   [Full Text] [Related]  

  • 11. Waiver of Intellectual Property Rights on COVID-19 vaccine roll out.
    Cabatbat KPM
    J Public Health (Oxf); 2022 Jun; 44(2):e338. PubMed ID: 34164670
    [No Abstract]   [Full Text] [Related]  

  • 12. Designing the global vaccine supply chain: balancing intellectual property rights with post COVID-19 vaccine equity.
    Park SP; Lee HJ; Yu Y; Lee EYJ; Park YS
    BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 38035734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The commitment for fair distribution of COVID-19 vaccine among all countries of the world.
    Sadeghi R; Masoudi MR; Khanjani N
    Res Nurs Health; 2021 Apr; 44(2):266-267. PubMed ID: 33522613
    [No Abstract]   [Full Text] [Related]  

  • 14. Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic.
    Altindis E
    Expert Rev Vaccines; 2022 Apr; 21(4):427-430. PubMed ID: 34878957
    [No Abstract]   [Full Text] [Related]  

  • 15. Equitable distribution of COVID-19 vaccines.
    Burki T
    Lancet Infect Dis; 2021 Jan; 21(1):33-34. PubMed ID: 33357392
    [No Abstract]   [Full Text] [Related]  

  • 16. Temporary waiver of intellectual property on Covid-19 vaccines: toward the creation of a better, post-pandemic society.
    Del Castillo FA
    J Public Health (Oxf); 2021 Sep; 43(3):e559-e560. PubMed ID: 34056662
    [No Abstract]   [Full Text] [Related]  

  • 17. Applications of telemedicine in the supply and distribution of COVID-19 vaccines in Africa.
    Okereke M; Babatunde AO; Samuel ST; Ogunkola IO; Mogessie YG; Lucero-Prisno DE
    J Glob Health; 2021 Mar; 11():03039. PubMed ID: 33828830
    [No Abstract]   [Full Text] [Related]  

  • 18. A Global Intellectual Property Waiver is Still Needed to Address the Inequities of COVID-19 and Future Pandemic Preparedness.
    Amin T; Kesselheim AS
    Inquiry; 2022; 59():469580221124821. PubMed ID: 36124939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why is it so hard for general practice to provide COVID-19 vaccines?
    Weenink V
    N Z Med J; 2021 Apr; 134(1534):114-117. PubMed ID: 33927443
    [No Abstract]   [Full Text] [Related]  

  • 20. Exploring risks of investor claims brought forth after the TRIPS waiver for COVID-19.
    Kulkarni SM; Kaur V
    Pharm Pat Anal; 2022 Nov; 11(6):165-174. PubMed ID: 36314462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.